Gibson Dunn Advises BVF Partners L.P. on up to $24.5 Million Financing for Entera Bio
For Entera Bio Ltd., a clinical stage company focused on creating oral peptide and protein replacement therapies for major unmet medical needs where an oral tablet form holds the potential to transform the standard of care, Gibson Dunn represented BVF Partners L.P. in its up to $24.5 million private placement financing.